Innovative Drug Synthesis

This book covers all aspects of the medicinal chemistry of the latest drugs, and the cutting-edge science associated with them. Following the editors’ 3 successful drug synthesis books, this provides expert analysis of the pros and cons of different synthetic routes and demystifies the process of modern drug discovery for practitioners and researchers.

‧ Summarizes for each drug: respective disease area, important properties and SAR (structure-activity relationship), and chemical synthesis routes / options
‧ Includes case studies in each chapter
‧ Illustrates how chemistry, biology, pharmacokinetics, and a host of disciplines come together to produce successful medicines
‧ Explains the advantages of process synthesis versus the synthetic route for drug discovery

Jie Jack Li is an Associate Professor of chemistry at the University of San Francisco. Previously, he was a chemist at Bristol-Myers Squibb Company. He has authored or edited several books published by Wiley, includingDrug Discovery: Practices, Processes, and Perspectives, Heterocyclic Chemistry in Drug Discovery,Name Reactions in Heterocyclic Chemistry, Name Reactions for Functional Group Transformations,Contemporary Drug Synthesis, The Art of Drug Synthesis, and Modern Drug Synthesis.

Douglas Johnson is an Associate Research Fellow and head of Chemical Biology in the Neuroscience Medicinal Chemistry group at Pfizer Worldwide Research and Development. He is a co-author on more than 70 publications and patents and is a co-author of the book Contemporary Drug Synthesis and is an editor of The Art of Drug Synthesis, andModern Drug Synthesis (all published by Wiley).